Wild type transthyretin cardiac amyloidosis (wtATTR) and heart failure with reduced ejection fraction (HFrEF): can angiotensin receptor/neprilysin inhibitors be a therapeutic option?

20 May 2023 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease 2 Myocardial Disease HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by